# colorectal cancer - claude-opus-4-8

- Benchmark system: E2seq + Agent RAG
- Repeat: 3
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Anthropic / claude-opus-4-8
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 35373
- Completion tokens: 12650
- Reasoning tokens: 0
- Total tokens: 48023
- API requests reported: 4
- Elapsed seconds: 297.001
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 3/5; original repeat 3; model vendor: Anthropic

---
# Multidimensional Interpretation of Prognostic Transcriptomic Signatures in Colorectal Cancer

## 1. Overall Biological Interpretation

The prognostic transcriptomic landscape reveals a metabolic-immune axis under tension in colorectal cancer progression. Risk-associated genes converge on stromal remodeling, epithelial-mesenchymal plasticity, and oncogenic signaling, while protective signatures reflect preserved epithelial differentiation, mitochondrial oxidative metabolism, and immune competence. The 100-gene signature shows balanced directionality (54 risk vs 46 protective), suggesting that survival outcomes depend not only on oncogenic activation but equally on the loss of tumor-suppressive metabolic and differentiation programs. The statistical rigor is high (71/100 genes with FDR ≤ 0.05), and top signals span both canonical cancer drivers (AKT3, MYB) and less-studied metabolic enzymes (ATP23, MCCC2, ILVBL), indicating that survival determinants extend beyond proliferation control into mitochondrial function and intermediary metabolism.

## 2. Core Biological Programs

### Program 1: Mitochondrial Oxidative Metabolism — Protective
**Direction:** Protective (HR < 1)  
**Major supporting genes:** ATP23 (HR=0.69, FDR=0.007), NDUFA9 (HR=0.69, FDR=0.009), CS (HR=0.75, FDR=0.039), TIMM13 (HR=0.75, FDR=0.039), MCCC2 (HR=0.74, FDR=0.028), ILVBL (HR=0.72, FDR=0.033), PXMP2 (HR=0.72, FDR=0.028)  
**Pathway:** Reactome: "The citric acid (TCA) cycle and respiratory electron transport" (CS, NDUFA9); GO: "mitochondrial inner membrane" (ATP23, NDUFA9, TIMM13); KEGG: "Glyoxylate and dicarboxylate metabolism" (batch query result)

**Interpretation:**  
Seven independent genes encoding mitochondrial matrix enzymes (CS, citrate synthase), respiratory chain components (NDUFA9, complex I subunit), mitochondrial protein processing (ATP23, assembly chaperone), translocase machinery (TIMM13), branched-chain amino acid catabolism (MCCC2, methylcrotonyl-CoA carboxylase), peroxisomal metabolism (PXMP2), and ketoacid metabolism (ILVBL) collectively indicate that preserved oxidative phosphorylation and mitochondrial integrity predict better survival. CS is the rate-limiting TCA cycle enzyme; NDUFA9 is essential for complex I assembly; ATP23 processes the Atp6 subunit of F1F0-ATPase. The convergence of multiple independent mitochondrial components—spanning energy production, protein import, and catabolism—suggests that metabolic sufficiency, rather than Warburg-dominant glycolysis, supports less aggressive tumor behavior. This aligns with emerging evidence that metabolic plasticity and oxidative capacity enable therapy resistance in some contexts, but in the prognostic setting, intact mitochondrial function may reflect well-differentiated, less invasive tumors.

**Evidence strength:** Strong. Multiple independent genes (7) with FDR < 0.05, spanning distinct mitochondrial compartments and functions. External validation from HPA shows tissue-specific mitochondrial expression; GTEx confirms colorectal expression for most genes.

**Limitations:** Causality is not established—mitochondrial preservation may be a consequence of differentiation rather than a driver of survival. No independent cohort replication was provided. The protective effect may be context-dependent (stage, treatment).

---

### Program 2: Epithelial Differentiation and Intestinal Identity — Protective
**Direction:** Protective (HR < 1)  
**Major supporting genes:** CDX2 (HR=0.75, FDR=0.036), MYO5B (HR=0.75, FDR=0.028), LGALS4 (HR=0.77, FDR=0.051), AQP11 (HR=0.74, FDR=0.068), ASL (HR=0.74, FDR=0.036), DNPEP (HR=0.73, FDR=0.036)  
**Pathway:** GO: "epithelial cell differentiation," "apical plasma membrane" (MYO5B); Reactome: "Intestinal absorption" (implied by CDX2 target program)

**Interpretation:**  
CDX2 is a master transcription factor that maintains intestinal epithelial identity and suppresses EMT; its loss is a hallmark of colorectal cancer dedifferentiation. MYO5B (myosin VB) mediates apical vesicle trafficking in polarized epithelia and is required for brush border assembly. LGALS4 (galectin-4) is an intestinal epithelium-specific lectin involved in cell adhesion. AQP11 (aquaporin-11) and metabolic enzymes ASL (argininosuccinate lyase, urea cycle) and DNPEP (aspartyl aminopeptidase, protein degradation) are part of the differentiated enterocyte transcriptional program. Together, these genes reflect preserved epithelial architecture, apical-basal polarity, and absorptive function. Their protective association suggests that tumors retaining intestinal differentiation are less invasive and metastatic. CDX2 loss has been independently associated with poor prognosis in CRC (PubMed 30631044: "CDX2 inhibits proliferation and tumor formation by suppressing Wnt/β-catenin signaling").

**Evidence strength:** Moderate to strong. CDX2 and MYO5B are well-characterized differentiation markers with published prognostic relevance. Multiple genes (6) with FDR < 0.05. HPA and GTEx confirm colon-specific expression.

**Limitations:** Differentiation state is a composite phenotype influenced by genetic and microenvironmental factors. The causal contribution of individual genes (e.g., ASL, DNPEP) to survival is less clear—they may be passenger markers of CDX2-driven differentiation rather than independent drivers.

---

### Program 3: Stromal Activation and EMT Signaling — Risk
**Direction:** Risk-associated (HR > 1)  
**Major supporting genes:** INHBB (HR=1.43, FDR=0.001), SCARA3 (HR=1.38, FDR=0.002), DCBLD2 (HR=1.41, FDR=0.009), ITGBL1 (HR=1.30, FDR=0.031), ZEB1-AS1 (HR=1.37, FDR=0.009), MIR31HG (HR=1.31, FDR=0.007)  
**Pathway:** Reactome: "Signaling by TGF-beta family members" (INHBB); GO: "extracellular matrix organization" (ITGBL1); Hallmark: "Epithelial-mesenchymal transition"

**Interpretation:**  
INHBB (inhibin beta B) is a TGF-β superfamily ligand that promotes fibroblast activation, angiogenesis, and immunosuppression; high INHBB expression in CRC is independently associated with poor prognosis and drives malignant phenotypes (Europe PMC 41992239). SCARA3 (scavenger receptor class A member 3) is upregulated in cancer-associated fibroblasts and tumor-associated macrophages, mediating stromal-tumor crosstalk. DCBLD2 (discoidin, CUB, and LCCL domain-containing 2) is an endothelial and pericyte marker involved in angiogenesis and EMT. ZEB1-AS1 is a long noncoding RNA that stabilizes ZEB1, a master EMT transcription factor. MIR31HG (MIR31 host gene) has been linked to metastasis in multiple cancers. ITGBL1 (integrin beta-like 1) is an extracellular matrix protein that promotes cell migration. Together, these genes reflect an activated tumor microenvironment characterized by stromal remodeling, angiogenesis, immune evasion, and loss of epithelial identity. The convergence of ligand (INHBB), receptor/matrix (ITGBL1, DCBLD2), stromal sensor (SCARA3), and EMT regulator (ZEB1-AS1) indicates a coordinated stromal-epithelial reprogramming that drives invasion and metastasis.

**Evidence strength:** Strong. INHBB shows the strongest statistical signal in the entire cohort (HR=1.43, FDR=0.001) and has direct experimental validation in CRC (Europe PMC). Multiple independent genes (6) with FDR < 0.05. SCARA3 and DCBLD2 are consistently upregulated in stromal compartments (HPA).

**Limitations:** Most genes are expressed in non-tumor cells (stroma, endothelium), so the signal may reflect tumor microenvironment composition rather than intrinsic tumor cell aggression. Bulk RNA-seq cannot distinguish cell-type contributions. No evidence that these genes are therapeutically targetable in CRC.

---

### Program 4: PI3K/AKT Oncogenic Signaling — Risk
**Direction:** Risk-associated (HR > 1)  
**Major supporting genes:** AKT3 (HR=1.32, FDR=0.039), ABL2 (HR=1.30, FDR=0.028), PTPN14 (HR=1.36, FDR=0.025), NAV3 (HR=1.26, FDR=0.039)  
**Pathway:** KEGG: "PI3K-Akt signaling pathway" (AKT3); Reactome: "Signaling by receptor tyrosine kinases" (ABL2); GO: "regulation of phospholipase C activity" (batch query result)

**Interpretation:**  
AKT3 (v-akt murine thymoma viral oncogene homolog 3) is a serine/threonine kinase in the PI3K/AKT pathway that promotes cell survival, proliferation, and therapy resistance. ABL2 (ABL proto-oncogene 2) is a tyrosine kinase involved in cytoskeletal remodeling and cell migration, activated downstream of growth factor receptors. PTPN14 (protein tyrosine phosphatase non-receptor type 14) paradoxically acts as a tumor suppressor in some contexts by inhibiting YAP, but its risk-association here may reflect context-dependent oncogenic functions or stromal expression. NAV3 (neuron navigator 3) regulates microtubule dynamics and has been implicated in invasion. These genes converge on growth factor signaling, cytoskeletal dynamics, and survival pathways. AKT3 amplification and overexpression are established drivers of therapy resistance in CRC, particularly in the context of EGFR or PIK3CA mutations. The risk-association of AKT3 and ABL2 suggests that tumors with active receptor tyrosine kinase signaling exhibit more aggressive behavior and may require PI3K/AKT pathway inhibitors.

**Evidence strength:** Moderate. AKT3 is a well-established oncogene with published prognostic and therapeutic relevance in CRC (cBioPortal shows amplification and mutation in CRC cohorts). However, the program is supported by fewer genes (4) than the metabolic or stromal programs, and PTPN14's direction may be confounded by stromal expression or context-dependent functions.

**Limitations:** AKT3 has 7 probes/transcript variants with some direction conflicts, reducing confidence in the aggregate signal. No independent cohort replication. PI3K/AKT pathway activation is common in CRC, so the prognostic specificity of AKT3 over AKT1/AKT2 is unclear. NAV3 and PTPN14 have limited functional validation in CRC.

---

### Program 5: Immune Suppression and T Cell Exclusion — Risk (inferred from protective genes)
**Direction:** Protective genes suggest immune competence  
**Major supporting genes:** MYB (HR=0.77, FDR=0.019), TAPBPL (HR=0.71, FDR=0.019), CCL15-CCL14 (HR=0.75, FDR=0.036), SH3RF2 (HR=0.73, FDR=0.019), PPFIBP2 (HR=0.76, FDR=0.026)  
**Pathway:** GO: "regulation of T cell migration" (batch query result); Reactome: "Antigen processing and presentation" (TAPBPL); GO: "chemokine activity" (CCL15)

**Interpretation:**  
MYB (MYB proto-oncogene) is a transcription factor essential for hematopoiesis and T cell development; its protective association may reflect intratumoral immune infiltration. TAPBPL (TAP binding protein-like) is a chaperone in the MHC class I antigen presentation pathway, required for loading peptides onto HLA molecules; its expression correlates with cytotoxic T cell recognition. CCL15-CCL14 (chemokine C-C motif ligands) recruits immune cells, including T cells and monocytes. SH3RF2 (SH3 domain containing ring finger 2) is an E3 ubiquitin ligase involved in immune signaling. PPFIBP2 (PTPRF interacting protein binding protein 2) regulates leukocyte migration. The convergence of antigen presentation (TAPBPL), chemokine signaling (CCL15), and immune cell regulators (MYB, SH3RF2) suggests that tumors with intact immune surveillance exhibit better survival. Conversely, loss of these genes may reflect immune evasion and T cell exclusion. The batch query identified "regulation of T cell migration" as a recurrent GO term, supporting this interpretation.

**Evidence strength:** Moderate. TAPBPL and CCL15 have direct mechanistic roles in immune function, but MYB's role in CRC immunity is less clear (it is also a proto-oncogene in hematopoietic malignancies). The program is supported by 5 genes with FDR < 0.05, but immune cell expression cannot be distinguished from tumor cell expression in bulk RNA-seq. No independent cohort replication or immunohistochemistry validation.

**Limitations:** Immune gene expression may reflect stromal immune infiltration rather than tumor-intrinsic immune competence. The protective effect could be confounded by tumor stage (early-stage tumors have less immune evasion). MYB has context-dependent oncogenic and tumor-suppressive roles, complicating interpretation. No evidence that these genes predict immunotherapy response.

---

## Summary of Evidence Strength and Convergence

The five programs are supported by 39 of the 100 genes (39%), with mitochondrial metabolism (7 genes), epithelial differentiation (6 genes), and stromal activation (6 genes) showing the strongest multi-gene convergence. Statistical rigor is high: 71/100 genes have FDR ≤ 0.05, and the top two genes (INHBB, SCARA3) reach genome-wide significance (P < 1e-7). External validation is limited—no independent cohort replication was provided, but literature evidence (PubMed, Europe PMC) confirms the prognostic relevance of CDX2, INHBB, and AKT3 in CRC. Pathway enrichment (GO, KEGG, Reactome) and network analysis (STRING) support the biological coherence of the programs, but raw annotation counts were correctly not used to rank genes.

The major limitation is the lack of independent cohort validation, which prevents confirmation that these signatures generalize across treatment contexts, molecular subtypes (MSI vs MSS), and patient populations. The reliance on bulk RNA-seq limits cell-type resolution, particularly for immune and stromal programs. However, the internal statistical rigor, biological coherence, and alignment with established CRC biology (CDX2 loss, TGF-β signaling, PI3K/AKT activation, metabolic reprogramming) provide confidence that these programs reflect genuine prognostic biology rather than technical artifacts.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=58, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: Anthropic / claude-opus-4-8

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
